GlassScriptPhysician profile
Herschel Dean
NPI 1518004209
$5,465.51
in general payments reported to CMS, 2019-2025
38 companies · $510 in 2025
The $510 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,079 · 2020: $764 · 2021: $697 · 2022: $866 · 2023: $591 · 2024: $958 · 2025: $510.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,059.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,059.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $869.52 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Abbott Laboratories | $649.16 | 2019-2025 | Infinity, Freestyle Libre 3, Proclaim |
| Lilly USA, LLC | $445.08 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $436.77 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $401.11 | 2019-2024 | Gardasil, Gardasil 9, Capvaxive |
| Pfizer INC. | $398.54 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $370.09 | 2019-2024 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $327.53 | 2019-2022 | |
| Abbvie INC. | $154.88 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Astrazeneca Pharmaceuticals LP | $140.22 | 2019-2024 | Farxiga |
| Glaxosmithkline, LLC. | $133.15 | 2019-2025 | Arexvy, Shingrix |
| Antares Pharma, INC. | $121.84 | 2021-2024 | Xyosted, Tlando, Nocdurna |
| Janssen Pharmaceuticals, INC | $84.54 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $74.80 | 2023-2025 | Xifaxan |
| Genentech USA, INC. | $73.80 | 2019-2021 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $71.25 | 2024 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $67.43 | 2025 | Voquezna |
| Neos Therapeutics, LP | $55.95 | 2019-2023 | Adzenys Xr-Odt |
| Tris Pharma INC | $50.82 | 2023 | Dyanavel Xr |
| Shire North American Group INC | $50.28 | 2019 | |
| Corium, LLC | $47.89 | 2022-2024 | Azstarys |
| Amgen INC. | $47.84 | 2019-2022 | |
| Eisai INC. | $38.81 | 2020 | |
| Xeris Pharmaceuticals, INC. | $37.36 | 2023 | Gvoke Hypopen |
| Exact Sciences Corporation | $31.17 | 2025 | Cologuard Collection Kit |
| Allergan, INC. | $29.06 | 2019-2020 | |
| Sanofi Pasteur INC. | $28.20 | 2025 | |
| Astellas Pharma US INC | $28.16 | 2022 | |
| Acerus Pharmaceuticals Corporation | $26.54 | 2021-2022 | |
| Amarin Pharma, INC. | $26.51 | 2019 | |
| Insulet Corporation | $24.97 | 2025 | Omnipod |
| E.R. Squibb & Sons, L.L.C. | $24.69 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $21.30 | 2019 | |
| Supernus Pharmaceuticals, INC. | $19.60 | 2022 | |
| Esperion Therapeutics, INC. | $17.63 | 2020 | |
| Tolmar, INC. | $15.25 | 2025 | Jatenzo |
| Arbor Pharmaceuticals, INC. | $14.18 | 2019 | |
| Dynavax Technologies Corporation | $9.59 | 2025 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Herschel Dean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.